Biological communities are rarely stable. Their composition is constantly changing, depending on the environmental conditions in the respective ecosystems—and sometimes this change is so vast that ...
This is part two in our three-part GENcast series, where we discuss various aspects of the drug discovery and development process and, in particular, how advanced computational techniques like ...
The drug discovery and development process can be an arduous endeavor. Manufacturers spend considerable resources and money chasing down potential candidate molecules to create a potential new ...
The biopharmaceutical industry is rapidly moving from empirical, trial and error process development toward digitalized and ...
With fresh focus on New Approach Methodologies (NAMs) to move away from animal models in biosciences and preclinical ...
EMA proposes new guideline on model-informed drug development The European Medicines Agency (EMA) is planning to issue a draft guideline on the reporting and evaluation of new mechanistic models to ...
OSIRAM-1/TORG1833: Overall survival results of a randomized phase II study of osimertinib plus ramucirumab versus osimertinib alone as initial chemotherapy for EGFR mutation-positive non-squamous ...
Unfortunately, this book can't be printed from the OpenBook. If you need to print pages from this book, we recommend downloading it as a PDF. Visit NAP.edu/10766 to get more information about this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results